Q-omics provides the consensus-scored SDHCP2 profile across patient tissues and cancer cell-line models. SDHCP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, SDHCP2 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SDHCP2 RNA expression shows 7,830 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight TGCT, COAD, and GBM as cancer lineages where SDHCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHCP2 survival associations across molecular data types. SDHCP2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHCP2 RNA expression–survival associations across cancer types. High SDHCP2 expression shows unfavorable associations in TGCT, KICH, UCS, THYM and BLCA, but favorable associations in LUSC. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify TGCT as the clearest survival context for SDHCP2 RNA expression.
This table summarizes SDHCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SDHCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHCP2 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, BRCA and READ. The COAD box plot shows higher SDHCP2 RNA expression in tumor versus normal tissue (log2 FC = +0.429, t-test p < 0.001).
This table shows molecular features associated with SDHCP2 in patient tissues and cancer cell lines. In patient samples, SDHCP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
